Glaukos announced the FDA approved its new drug application, or NDA, for a single administration per eye of iDose TR 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure, or IOP, in patients with ocular hypertension, or OHT, or open-angle glaucoma, or OAG.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GKOS:
